We do offer a money-back guarantee of 14 days from the date of purchase with certain conditions.

Conditions must be met to qualify for a refund:

1 - Product is defective

2 - Product is not as described

3 - Product must be unopened

4 - Product must be in original packaging

5 - Product must be unused

6 - Product must not be damaged

We may decline a refund if the above conditions are not met.

Products on sale or clearance are not eligible for refunds.

The customers must get a return merchandise authorization (RMA) first.

The customers have to contact us before returning the product and pay the shipping costs for a return or exchange.

We do charge a restocking fee of 15% of the total amount paid.

Many women with hair loss want to accelerate hair growth. There are many hair growth remedies for women on the market to treat hair loss. ROGAINEⓇ has developed a product specifically for hair loss in women - ROGAINEⓇ Womensolution for hereditary hair loss (pack size: 180 ml). The special thing about ROGAINEⓇ is that it relies on the active ingredient minoxidil. It has proven itself in the case of hereditary hair loss in women, as it promotes hair growth. The hair follicles get better blood circulation and can therefore be better supplied with nutrients. The hair roots can be strengthened and the hair can grow over a longer period of time. This allows the cells to actively divide and renew themselves for longer. If the treatment is carried out as recommended, a first therapeutic success is already possible after 12 weeks.

Unless otherwise prescribed by the doctor, the medicine should be used as follows:

Apply 1 ml twice a day (morning and evening) to the affected areas of the scalp. The daily amount of 2 applications by 1 ml solution should not be exceeded, regardless of the size of the affected skin area.

Before applying the solution, please note the following things:

• The scalp must be dry before scalp or hair can be moistened;
• After applying the solution, your hands should be washed carefully to avoid accidental contact with mucous membranes and eyes;
• After the application of the solution, you should wait for at least 4 hours;
• The solution should not be applied to other parts of the body.

Duration of treatment:

The beginning and extent of hair growth vary for individual patients. The treatment should last at least 3 to 4 months until an effect can be expected. If the desired treatment success does not occur within 8 months, therapy should be discontinued.

Method and duration of application:

• Before applying the solution, make sure that the scalp is dry.
• The solution should not be applied to other parts of the body.
• After applying the solution, the hands should be washed carefully to avoid accidental contact with mucous membranes and the eyes.
• Clinical experience is available for a duration of 48 weeks.

Please read the instructions for use in the package leaflet before using ROGAINEⓇ Women's solution for hereditary hair loss (pack size: 180 ml).

The medicine should not be used by pregnant and lactating mothers, as no studies have been conducted on pregnant women and minoxidil may be excreted in breast milk.

Two to six weeks after the start of treatment, there may be a temporary increase in the number of failed hair. This can be a sign of the effectiveness of ROGAINEⓇ Women's solution in hereditary hair loss (pack size: 180 ml). The old hair gives way to the new ones.

Active ingredient: minoxidil. Area of application: ROGAINEⓇ Women stabilizes the course of androgenetic alopecia from the female in women. Type (characteristic plant-related diffuse scalp thinning in the crown area). The treatment with ROGAINEⓇ Women promotes hair growth and can thus counteract the progression of this hair loss.

Warning: Enth. Propylene glycol.

The preparation must not be used in case of:

• Known hypersensitivity to minoxidil or to any of the excipients of the medicine;
• Simultaneous use of other topical medicines on the scalp;
• Sudden or uneven hair loss;
• In children and adolescents under 18 years;
• During pregnancy and lactation;
• In patients with evidence of cardiovascular disease or heart rhythm disorders;
• In high blood pressure patients, including those undergoing antihypertensive therapy;